Sign in
CompletedNo phase

Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy

Key facts

Who runs it
University Medical Centre Ljubljana
Where
Slovenia2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
55 people enrolled
Started
15 Oct 2020
Ended
29 Feb 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lab tests
  • ECG
  • Cannabinoid Levels
  • Full-spectrum Medical Canabis Product (HemPhar)
  • Placebo
  • Spasticity level according to modified Ashworth scale (Bohannon)
  • Gross Motor Function Measure
  • Borg rating of perceived exertion scale
  • Edmonton symptom assessment system
Record updated
22 May 2024

Who can take part

Age
5 years to 25 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • With confirmed diagnosis of cerebral palsy (CP) and classified according to the Gross Motor Function Classification System (GMFCS) as level IV or V
  • With spastic unilateral or spastic bilateral type of CP
  • Those children/young adults whose parents/caregivers were informed about the aims of the study and have signed the Informed consent form

Who cannot take part

  • Other proven diseases/conditions with the prevalence of spastic type of muscle tone (e.g. neurodegenerative, metabolic, etc.), and children with liver disease
  • History of psychiatric illness/condition in the family
  • Other forms of CP (dyskinetic, ataxic)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The proposed study is a double-blind, placebo-controlled, cross over study on 60 children aged 5 to 25 years with severe spasticity related to cerebral palsy (CP), level IV and V with full-spectrum medical cannabis product of CBD/THC ratio 10:1.

The 2 groups in the trial

  • Active Substance: Full-spectrum Medical Canabis Product (HemPhar)Existing treatment, for comparison

    For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.

    Treatment: Lab tests, ECG, Cannabinoid Levels, Full-spectrum Medical Canabis Product (HemPhar), Spasticity level according to modified Ashworth scale (Bohannon), Gross Motor Function Measure, Borg rating of perceived exertion scale, and Edmonton symptom assessment system

  • PlaceboPlacebo, for comparison

    For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.

    Treatment: Lab tests, ECG, Placebo, Spasticity level according to modified Ashworth scale (Bohannon), Gross Motor Function Measure, Borg rating of perceived exertion scale, and Edmonton symptom assessment system

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Full-spectrum Medical Canabis Product (HemPhar) With a CBD:THC Ratio of 10:1 for Treatment of Spasticity in Children and Young Adults With Severe Forms of Cerebral Palsy
Record updated
22 May 2024